An observational study in Cancer, Pain and Opioid Analgesic Adverse Reaction, sponsored by University Hospital, Clermont-Ferrand. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Guastella V, Bianchi M, Hanniet E, Pereira B, Authier N. Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a mult…PubMed 41044384 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In oncology, pain is one of the main symptoms of discomfort. It has a significant impact on the quality of life.The use of opioid analgesics is recommended for the treatment of moderate to severe cancer pain.The misuse of opioid analgesics is an international public health problem.Different scales have been developed to help the prescriber screen for the risk of misuse in the general population. Patients with cancer-related pain are also at risk for aberrant opioid-related behaviors, misuse or addiction.
The main objectif of this study is to validate of the screening scale for the misuse of opioid analgesics in patients with chronic pain related to cancer. (Prescription Opioid Misuse Index - POMI).
The study takes place in 2 phases.
Test phase :
Questionnaire no. 1 constitutes the data for the TEST phase: it includes socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Concise Pain Questionnaire (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
Retest phase :
questionnaire no. 2 10 to 15 days later.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 138 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.
Browse Neoplasms studies →University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cancer patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Questionnaires
Other: Questionnaires
questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
POMI scale score - Prescription Opioid Misuse Index
8-item self-assessment scale
Time frame: day 1
POMI scale score - Prescription Opioid Misuse Index
8-item self-assessment scale
Time frame: day 15
QCD
Visual Analogue Scales (VAS) for assessing the intensity and daily impact of pain (0-10)
Time frame: day 1
QCD
Visual Analogue Scales (VAS) for assessing the intensity and daily impact of pain (0-10)
Time frame: day 15
Sociodemographic characteristics
Questionnaire about Sociodemographic characteristics of patients
Time frame: day 1
Lifestyle habits, other consumption
Questionnaire about Lifestyle habits, other consumption
Time frame: day 1
Analgesic treatments
Questionnaire about Ongoing analgesic treatments
Time frame: day 1
Use of analgesics
Question evaluating the use of analgesics in the context of anticipating pain
Time frame: day 1
Use of analgesics
Question evaluating the use of analgesics in the context of anticipating pain
Time frame: day 15
Ran from Feb 2023 to primary completion in Dec 2024, 22 months.
Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's 22 months is below that.
Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2024 → Dec 2024 and completion Apr 2025 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Guastella V, Bianchi M, Hanniet E, Pereira B, Authier N. Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a mult…PubMed 41044384 ↗
Guastella V, Bianchi M, Hanniet E, Pereira B, Authier N. Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a mult…PubMed 41044384 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →